Mycophenolate mofetil and Transferrin saturation decreased - a phase IV clinical study of FDA data

Summary:

Transferrin saturation decreased is reported as a side effect among people who take Mycophenolate mofetil (mycophenolate mofetil), especially for people who are female, 60+ old, also take Synthroid, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Transferrin saturation decreased when taking Mycophenolate mofetil. It is created by eHealthMe based on reports of 93,176 people who have side effects when taking Mycophenolate mofetil from the FDA, and is updated regularly.

What is Mycophenolate mofetil?

Mycophenolate mofetil has active ingredients of mycophenolate mofetil. It is often used in myasthenia gravis. eHealthMe is studying from 93,460 Mycophenolate mofetil users. Check the latest studies of Mycophenolate mofetil.

What is Transferrin saturation decreased?

Transferrin saturation decreased is found to be associated with 88 drugs and 228 conditions by eHealthMe. Check the latest studies of Transferrin saturation decreased.

On Jul, 11, 2026

93,176 people reported to have side effects when taking Mycophenolate mofetil.
Among them, 12 people (0.01%) have Transferrin saturation decreased.

Could Mycophenolate mofetil cause Transferrin saturation decreased?

Among these 12 people:

What is the gender of people who have Transferrin saturation decreased when taking Mycophenolate mofetil? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Transferrin saturation decreased when taking Mycophenolate mofetil? *

What are other drugs people take besides Mycophenolate mofetil? *

What are other side effects people have besides Transferrin saturation decreased? *

Fall: 9 people, 75.00%
Blood Iron Decreased: 9 people, 75.00%
Haemoglobin Decreased: 9 people, 75.00%
Headache (pain in head): 9 people, 75.00%
Mean Cell Haemoglobin Decreased (less than normal haemoglobin per red blood cell in a sample of blood): 7 people, 58.33%
Iron Binding Capacity Total Increased: 7 people, 58.33%
Mean Cell Volume Decreased (less of the average red blood cell volume): 7 people, 58.33%
Mean Cell Haemoglobin Concentration Decreased (less concentration of haemoglobin in a given volume of packed red blood cells): 7 people, 58.33%
Limb Injury: 7 people, 58.33%
Joint Swelling: 7 people, 58.33%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 58.33%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Mycophenolate mofetil and have Transferrin saturation decreased?

- Check whether Transferrin saturation decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mycophenolate mofetil:

Mycophenolate mofetil (93,460 reports)

Browse all side effects of Mycophenolate mofetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transferrin saturation decreased:

Transferrin saturation decreased (88 drugs)

Browse all the conditions that are associated with Transferrin saturation decreased:

Transferrin saturation decreased (228 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil (the active ingredients of Mycophenolate mofetil) and Mycophenolate mofetil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.